Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05600114 · ClinicalTrials.gov registry record · Phase 2
Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder
A Phase 2 study of Social Anxiety Disorder, sponsored by EmpowerPharm.
- Completed
- Registry status
- Phase 2
- Development phase
- 239
- Enrollment target
- 17
- Study locations
NCT05600114: Completed Phase 2 study of Social Anxiety Disorder, sponsored by EmpowerPharm.
NCT05600114 is a Phase 2 study of Social Anxiety Disorder that has completed, run by EmpowerPharm. The registered enrollment target is 239 participants, above the 153-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target (56% higher). The trial reports 17 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05600114, a Phase 2 study of Social Anxiety Disorder, has completed, sponsored by EmpowerPharm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 239 participants
- Enrollment target
- 17
- Study locations
Study Summary
A phase 2, multicenter, double-blind, parallel group, placebo-controlled, randomized clinical study, designed to compare the efficacy, safety, and tolerability of 2 dose levels of CBD and a matching placebo for the treatment of subjects with Social Anxiety Disorder (SAD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cannabidiol oral solution
Study Locations (17)
California
- EPI-CBD-001 Site - Encino
- EPI-CBD-001 Site - Lemon Grove
- EPI-CBD-001 Site - Los Alamitos
- EPI-CBD-001-Site - Oceanside
- EPI-CBD-001 site - San Jose
Florida
- EPI-CBD-001 Site - Jacksonville
- EPI-CBD-001 Site - Lauderhill
- EPI-CBD-001 Site - Maitland
- EPI-CBD-001 Site - Orlando
New York
- EPI-CBD-001 Site - Cedarhurst
- EPI-CBD-001-Site - New York
- EPI-CBD-001-Site - Rochester
Illinois
- EPI-CBD-001 Site - Chicago
Oklahoma
- EPI-CBD-001 Site - Oklahoma City
Oregon
- EPI-CBD-001 Site - Portland
Texas
- EPI-CBD-001 site - Wichita Falls
Washington
- EPI-CBD-001 Site - Bellevue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2022-10-27 |
| Est. Completion | 2023-12-13 |
| Phase | Phase 2 |
What the finished NCT05600114 record still lists
NCT05600114 is an interventional study that assigns participants to a tested intervention. The registered 239 participants enrollment target is mid-sized for trials with a published cap, above the 153-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target (56% higher).
The record links to 1 condition, with Social Anxiety Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05600114 lists 17 locations in 8 states (California, Florida, New York).
Frequently Asked Questions
What is clinical trial NCT05600114 about?
NCT05600114 is a clinical study titled "Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder". A phase 2, multicenter, double-blind, parallel group, placebo-controlled, randomized clinical study, designed to compare the efficacy, safety, and tolerability of 2 dose levels of CBD and a matching placebo for the treatment of subjects with Social Anxiety Disorder (SAD).
What is the current status of trial NCT05600114?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 239 participants. The study started on 2022-10-27. Estimated completion is 2023-12-13.
What conditions does trial NCT05600114 study?
This clinical trial studies the following conditions: Social Anxiety Disorder.
What interventions are being tested in trial NCT05600114?
The interventions under investigation include: Placebo (DRUG), Cannabidiol oral solution (DRUG).
Who is sponsoring clinical trial NCT05600114?
This trial is sponsored by EmpowerPharm, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05600114 being conducted?
This trial has 17 study locations across California, Florida, Illinois, New York, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05600114's enrollment target sits among peer trials
239 8th of 32 higher than 25 of 32 other Social Anxiety Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Social Anxiety Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
RECRUITING · Phase 2
-
Cannabidiol as a Treatment for Social Anxiety Disorder (R61)
COMPLETED · Phase 2
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Individual Factors of CBT Underlying Success
RECRUITING · NA
-
Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4
RECRUITING · NA
-
Very Brief Exposure: Development of a Novel Exposure Modality for Social Anxiety Disorder in Transition-Age Youth
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI